Database→Ipamorelin

Tier 3–4HormonalWeight LossAnti-agingPREMIUM

Ipamorelin

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) · Selective GHS-R1a Agonist

Not FDA-approved. Never approved anywhere in the world. Removed from FDA Category 2 list September 2024; under Pharmacy Compounding Advisory Committee review as of March 2026. WADA prohibited at all times (ghrelin mimetic). Only completed human RCT failed primary endpoint.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Ipamorelin is a selective GHS-R1a (ghrelin receptor) agonist and the first GH secretagogue documented not to stimulate ACTH or cortisol even at 200x therapeutic doses. Its only completed published human RCT -- a Phase 2 trial for postoperative ileus -- failed its primary endpoint (P=0.15), ending the pharmaceutical development program. All body composition and anti-aging claims are extrapolations from GH biology with no direct human trial evidence.

🔒

Full Profile: Premium Members Only

The complete Ipamorelin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use